Abstract

Objective: To determine the efficacy and safety of 100mg/ml intradermal tranexamic acid for the treatment of melasma.
Methodology: The study was conducted at Department of Dermatology, Dow University Hospital, Ojha campus, Karachi from 1st September 2023 to 29th February 2024 and included 60 patients selected by non-probability consecutive sampling technique. All diagnosed patients of melasma were included in the study. A detailed demographic and medical history were taken along with the Wood’s lamp examination. We administered 100mg/ml tranexamic undiluted injection intradermally at the site of melasma. A total of six sessions were carried out every 2 weeks for 3 months. Modified Melasma Area and Severity Index (mMASI) score was calculated on the first and last visit to evaluate efficacy of treatment.
Results: At first visit mean of mMASI was 6.43±3.57 (range 1.2-18.0), which showed significant reduction to 3.94±2.74 (range 0.3-13.8) at last visit (p

Key words: Melasma, mesotherapy, tranexamic acid.